Clinical Trial
doi: 10.1016/s0924-977x(99)00044-9.
Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients
Affiliations
- PMID: 10647091
- DOI: 10.1016/s0924-977x(99)00044-9
Item in Clipboard
Clinical Trial
Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients
Eur Neuropsychopharmacol.
1999 Dec.
Abstract
The dopamine D3 receptor (DRD3) appears to play an important role in the mediation of antipsychotic drug action. Genetic association of treatment response to the atypical antipsychotic drug clozapine with the DRD3 polymorphism Ser9Gly was investigated in a sample of 32 schizophrenic patients. We found association of treatment response with allele Gly-9 (P=0.0058) and with genotypes consisting of Gly-9 (P=0.033) by this pharmacogenetic approach. A combined analysis with two previous studies (Shaikh et al., Hum. Genet. 97 (1996) 714-719; Malhotra et al., Mol. Psychiatry 3 (1998) 72-75) further substantiates these results (P=0.0041).
Similar articles
-
The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.Mol Psychiatry. 1998 Jan;3(1):72-5. doi: 10.1038/sj.mp.4000288. Mol Psychiatry. 1998. PMID: 9491816
-
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):1-5. doi: 10.1002/ajmg.b.20045. Am J Med Genet B Neuropsychiatr Genet. 2004. PMID: 14681904
-
Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.Sao Paulo Med J. 2006 May 4;124(3):165-7. doi: 10.1590/s1516-31802006000300013. Sao Paulo Med J. 2006. PMID: 17119697
-
Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.Pharmacogenomics. 2004 Sep;5(6):691-8. doi: 10.1517/14622416.5.6.691. Pharmacogenomics. 2004. PMID: 15335289 Review.
-
[Pharmacogenetics and treatment response in schizophrenia].Encephale. 2007 Dec;33(6):954-64. doi: 10.1016/j.encep.2007.01.004. Epub 2007 Sep 4. Encephale. 2007. PMID: 18789788 Review. French.
Cited by
-
Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.Int J Mol Sci. 2023 Mar 21;24(6):5945. doi: 10.3390/ijms24065945. Int J Mol Sci. 2023. PMID: 36983018 Free PMC article. Review.
-
Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review.Genes (Basel). 2023 Mar 10;14(3):689. doi: 10.3390/genes14030689. Genes (Basel). 2023. PMID: 36980961 Free PMC article. Review.
-
Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Front Pharmacol. 2022 Oct 12;13:1005702. doi: 10.3389/fphar.2022.1005702. eCollection 2022. Front Pharmacol. 2022. PMID: 36313375 Free PMC article. Review.
-
Treatment-resistant schizophrenia: How far have we traveled?Front Psychiatry. 2022 Aug 30;13:994425. doi: 10.3389/fpsyt.2022.994425. eCollection 2022. Front Psychiatry. 2022. PMID: 36111312 Free PMC article.
-
Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behav Sci (Basel). 2021 Jun 30;11(7):97. doi: 10.3390/bs11070097. Behav Sci (Basel). 2021. PMID: 34209185 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
